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The objective was to review the evidence of effectiveness of the polyvalent polysaccharide pneu-
mococcal vaccine from prospective properly randomised controlled trials comparing pneumococ-
cal vaccines with placebo in subjects who are immunocompetent and those likely to have an
impaired immune system.
Databases searched included the Cochrane Library, (issue 2, 2000), MEDLINE (1966-August 2000),
PubMed (to August 2000) and EMBASE ( to August 2000). Reference lists of reports and reviews
were also searched. To be included in the analysis, a study had to have been a prospective ran-
domised comparison of a polysaccharide pneumococcal vaccine (any valency) and to have a placebo
or no treatment comparison group. Papers had to report important clinical outcomes, such as rates
of pneumonia, pneumococcal pneumonia, lower respiratory tract infections, pneumonia deaths or
bacteraemia. Serological outcomes were not sought. 
Thirteen randomised comparisons with over 45,000 subjects were identified in an extensive liter-
ature review. Eight studies had a quality score of 3 or more on a scale of 1 to 5. In three compar-
isons with 21,152 immunocompetent subjects (South African gold miners, New Guinea
highlanders) pneumococcal vaccination was effective in reducing the incidence of all-cause pneu-
monia (relative risk 0.56, 95% confidence interval 0.47 to 0.66), pneumococcal pneumonia (0.16;
0.11 to 0.23), pneumonia deaths (0.70; 0.50 to 0.96) and bacteraemia (0.18; 0.09 to 0.34). In ten
comparisons in over 24,000 people who were elderly or likely to have impaired immune systems,
pneumococcal vaccination was without effect for any outcome.
Present guidelines recommend pneumococcal vaccination for "high-risk" groups. There is no evi-
dence from randomised trials that this is of any benefit.
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Figure 1
Effect of pneumoccocal vaccination on all cause pneumonia in 
people who were immunocompetent (filled circles) and 
immunocompromised or elderly (open circles). Size of sym-
bol is proportional to number of people in the trial.
All pneumonias
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Effect of pneumoccocal vaccination on pneumoccocal pneu-
monia in people who were immunocompetent (filled circles) 
and immunocompromised or elderly (open circles). Size of 
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Effect of pneumoccocal vaccination on lower respiratory tract 
infection in people who were immunocompetent (filled cir-
cles) and immunocompromised or elderly (open circles). Size 
of symbol is proportional to number of people in the trial.
Figure 4
Effect of pneumoccocal vaccination on pneumonia deaths in 
people who were immunocompetent (filled circles) and im-
munocompromised or elderly (open circles). Size of symbol is 
proportional to number of people in the trial.
Pneumonia death
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Effect of pneumoccocal vaccination on bacteraemia in people 
who were immunocompetent (filled circles) and immunocom-
promised or elderly (open circles). Size of symbol is propor-
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Quality scores are R = randomised, DB = double-blinding, W = Withdrawals (Jadad et al, 1996)
Randomised studies of pneumococcal vaccination
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Main outcomes of randomized trials of pneumococcal vaccines








Relative risk (95%CI) Number-needed-to-treat 
(95%CI)
All pneumonias Healthy immuno-
competent
3 14 567 6.5 3.1 0.56 (0.47 to 0.66) 29 (24 to 36)





3 14 567 3.1 0.5 0.16 (0.11 to 0.23) 38 (33 to 45)





2 10 067 5.6 4.1 0.85 (0.71 to 1.02)





1 11 958 1.6 1.1 0.70 (0.50 to 0.96) 213 (114 to 1660)





1 5 427 3.8 0.7 0.18 (0.09 to 0.34) 32 (26 to 44)
Elderly or high risk 3 927 1.4 0.8 0.53 (0.14 to 1.94)
Note:  Details of patient groups are given in the text Numbers-needed-to-treat are only given where there is a statistical benefit of treatment over control.
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